nodes	percent_of_prediction	percent_of_DWPC	metapath
Boceprevir—ABCB1—Topotecan—cervical cancer	0.241	0.625	CbGbCtD
Boceprevir—CYP3A4—Topotecan—cervical cancer	0.144	0.375	CbGbCtD
Boceprevir—CTSL—exocrine gland—cervical cancer	0.0226	0.0626	CbGeAlD
Boceprevir—Pleuritic pain—Topotecan—cervical cancer	0.0195	0.128	CcSEcCtD
Boceprevir—CTSS—exocrine gland—cervical cancer	0.0149	0.0413	CbGeAlD
Boceprevir—CTSV—uterine cervix—cervical cancer	0.0119	0.033	CbGeAlD
Boceprevir—CTSV—decidua—cervical cancer	0.0114	0.0315	CbGeAlD
Boceprevir—CTSV—renal system—cervical cancer	0.0112	0.0309	CbGeAlD
Boceprevir—CTSV—endometrium—cervical cancer	0.0108	0.0299	CbGeAlD
Boceprevir—CTSV—mammalian vulva—cervical cancer	0.0104	0.0289	CbGeAlD
Boceprevir—CMA1—mammalian vulva—cervical cancer	0.00997	0.0276	CbGeAlD
Boceprevir—CTSL—epithelium—cervical cancer	0.00983	0.0272	CbGeAlD
Boceprevir—CTSL—uterine cervix—cervical cancer	0.00974	0.027	CbGeAlD
Boceprevir—CTSL—decidua—cervical cancer	0.00928	0.0257	CbGeAlD
Boceprevir—CTSL—renal system—cervical cancer	0.00911	0.0253	CbGeAlD
Boceprevir—CTSV—female reproductive system—cervical cancer	0.00894	0.0248	CbGeAlD
Boceprevir—CTSL—endometrium—cervical cancer	0.00881	0.0244	CbGeAlD
Boceprevir—CMA1—female reproductive system—cervical cancer	0.00853	0.0236	CbGeAlD
Boceprevir—CTSL—mammalian vulva—cervical cancer	0.00852	0.0236	CbGeAlD
Boceprevir—CTSV—female gonad—cervical cancer	0.00813	0.0225	CbGeAlD
Boceprevir—CTSL—uterus—cervical cancer	0.00812	0.0225	CbGeAlD
Boceprevir—CTSV—vagina—cervical cancer	0.00808	0.0224	CbGeAlD
Boceprevir—CTSK—uterine cervix—cervical cancer	0.00734	0.0203	CbGeAlD
Boceprevir—CTSL—female reproductive system—cervical cancer	0.0073	0.0202	CbGeAlD
Boceprevir—CTSK—decidua—cervical cancer	0.00699	0.0194	CbGeAlD
Boceprevir—CTSK—renal system—cervical cancer	0.00687	0.019	CbGeAlD
Boceprevir—CTSL—female gonad—cervical cancer	0.00664	0.0184	CbGeAlD
Boceprevir—CTSK—endometrium—cervical cancer	0.00664	0.0184	CbGeAlD
Boceprevir—CTSL—vagina—cervical cancer	0.0066	0.0183	CbGeAlD
Boceprevir—CTSS—uterine cervix—cervical cancer	0.00643	0.0178	CbGeAlD
Boceprevir—CTSK—mammalian vulva—cervical cancer	0.00642	0.0178	CbGeAlD
Boceprevir—CTSS—decidua—cervical cancer	0.00613	0.017	CbGeAlD
Boceprevir—CTSK—uterus—cervical cancer	0.00612	0.017	CbGeAlD
Boceprevir—CTSS—renal system—cervical cancer	0.00602	0.0167	CbGeAlD
Boceprevir—CTSS—endometrium—cervical cancer	0.00582	0.0161	CbGeAlD
Boceprevir—CTSS—mammalian vulva—cervical cancer	0.00563	0.0156	CbGeAlD
Boceprevir—Neuralgia—Topotecan—cervical cancer	0.00563	0.037	CcSEcCtD
Boceprevir—CTSK—female reproductive system—cervical cancer	0.0055	0.0152	CbGeAlD
Boceprevir—CTSS—uterus—cervical cancer	0.00536	0.0149	CbGeAlD
Boceprevir—Rash erythematous—Topotecan—cervical cancer	0.0051	0.0336	CcSEcCtD
Boceprevir—CTSK—female gonad—cervical cancer	0.005	0.0139	CbGeAlD
Boceprevir—CMA1—lymph node—cervical cancer	0.00499	0.0138	CbGeAlD
Boceprevir—CTSK—vagina—cervical cancer	0.00497	0.0138	CbGeAlD
Boceprevir—CTSS—female reproductive system—cervical cancer	0.00482	0.0134	CbGeAlD
Boceprevir—CTSS—female gonad—cervical cancer	0.00438	0.0121	CbGeAlD
Boceprevir—CTSS—vagina—cervical cancer	0.00436	0.0121	CbGeAlD
Boceprevir—Hyperbilirubinaemia—Topotecan—cervical cancer	0.0043	0.0283	CcSEcCtD
Boceprevir—CTSL—lymph node—cervical cancer	0.00427	0.0118	CbGeAlD
Boceprevir—Bone pain—Topotecan—cervical cancer	0.00408	0.0268	CcSEcCtD
Boceprevir—Respiratory failure—Topotecan—cervical cancer	0.00398	0.0262	CcSEcCtD
Boceprevir—Pulmonary embolism—Topotecan—cervical cancer	0.00391	0.0257	CcSEcCtD
Boceprevir—Colitis—Topotecan—cervical cancer	0.00375	0.0247	CcSEcCtD
Boceprevir—Rash maculo-papular—Topotecan—cervical cancer	0.00355	0.0234	CcSEcCtD
Boceprevir—Neoplasm—Topotecan—cervical cancer	0.00353	0.0232	CcSEcCtD
Boceprevir—Sepsis—Topotecan—cervical cancer	0.00339	0.0223	CcSEcCtD
Boceprevir—CTSL—MHC class II antigen presentation—HLA-DPB1—cervical cancer	0.00331	0.0326	CbGpPWpGaD
Boceprevir—CTSV—MHC class II antigen presentation—HLA-DPB1—cervical cancer	0.00331	0.0326	CbGpPWpGaD
Boceprevir—CTSK—lymph node—cervical cancer	0.00322	0.00891	CbGeAlD
Boceprevir—Lethargy—Topotecan—cervical cancer	0.0029	0.019	CcSEcCtD
Boceprevir—CTSV—Endochondral Ossification—FGFR3—cervical cancer	0.00287	0.0282	CbGpPWpGaD
Boceprevir—CTSS—lymph node—cervical cancer	0.00282	0.00781	CbGeAlD
Boceprevir—CTSK—MHC class II antigen presentation—HLA-DPB1—cervical cancer	0.00275	0.027	CbGpPWpGaD
Boceprevir—CTSL—Class I MHC mediated antigen processing & presentation—UBE3A—cervical cancer	0.00269	0.0265	CbGpPWpGaD
Boceprevir—CTSV—Class I MHC mediated antigen processing & presentation—UBE3A—cervical cancer	0.00269	0.0265	CbGpPWpGaD
Boceprevir—CTSL—MHC class II antigen presentation—HLA-DQB1—cervical cancer	0.00259	0.0255	CbGpPWpGaD
Boceprevir—CTSV—MHC class II antigen presentation—HLA-DQB1—cervical cancer	0.00259	0.0255	CbGpPWpGaD
Boceprevir—CTSL—Primary Focal Segmental Glomerulosclerosis FSGS—NOTCH1—cervical cancer	0.00245	0.0241	CbGpPWpGaD
Boceprevir—Pancytopenia—Topotecan—cervical cancer	0.00233	0.0153	CcSEcCtD
Boceprevir—Neutropenia—Topotecan—cervical cancer	0.00229	0.0151	CcSEcCtD
Boceprevir—CTSS—MHC class II antigen presentation—HLA-DPB1—cervical cancer	0.00226	0.0223	CbGpPWpGaD
Boceprevir—Pneumonia—Topotecan—cervical cancer	0.0022	0.0145	CcSEcCtD
Boceprevir—Infestation NOS—Topotecan—cervical cancer	0.00219	0.0144	CcSEcCtD
Boceprevir—Infestation—Topotecan—cervical cancer	0.00219	0.0144	CcSEcCtD
Boceprevir—Neuropathy peripheral—Topotecan—cervical cancer	0.00214	0.0141	CcSEcCtD
Boceprevir—CTSK—MHC class II antigen presentation—HLA-DQB1—cervical cancer	0.00214	0.0211	CbGpPWpGaD
Boceprevir—CYP3A5—uterine cervix—cervical cancer	0.00214	0.00592	CbGeAlD
Boceprevir—Stomatitis—Topotecan—cervical cancer	0.00213	0.014	CcSEcCtD
Boceprevir—Hepatobiliary disease—Topotecan—cervical cancer	0.00207	0.0136	CcSEcCtD
Boceprevir—Epistaxis—Topotecan—cervical cancer	0.00206	0.0136	CcSEcCtD
Boceprevir—CYP3A5—renal system—cervical cancer	0.002	0.00554	CbGeAlD
Boceprevir—Rhinitis—Topotecan—cervical cancer	0.00197	0.0129	CcSEcCtD
Boceprevir—Hypoaesthesia—Topotecan—cervical cancer	0.00195	0.0128	CcSEcCtD
Boceprevir—Pharyngitis—Topotecan—cervical cancer	0.00195	0.0128	CcSEcCtD
Boceprevir—CTSK—RANKL/RANK Signaling Pathway—MTOR—cervical cancer	0.00189	0.0186	CbGpPWpGaD
Boceprevir—CTSS—Class I MHC mediated antigen processing & presentation—UBE3A—cervical cancer	0.00184	0.0181	CbGpPWpGaD
Boceprevir—Angiopathy—Topotecan—cervical cancer	0.00178	0.0117	CcSEcCtD
Boceprevir—Immune system disorder—Topotecan—cervical cancer	0.00177	0.0117	CcSEcCtD
Boceprevir—Mediastinal disorder—Topotecan—cervical cancer	0.00177	0.0116	CcSEcCtD
Boceprevir—CTSS—MHC class II antigen presentation—HLA-DQB1—cervical cancer	0.00176	0.0174	CbGpPWpGaD
Boceprevir—Chills—Topotecan—cervical cancer	0.00176	0.0116	CcSEcCtD
Boceprevir—Alopecia—Topotecan—cervical cancer	0.00173	0.0114	CcSEcCtD
Boceprevir—Malnutrition—Topotecan—cervical cancer	0.00171	0.0112	CcSEcCtD
Boceprevir—Back pain—Topotecan—cervical cancer	0.00165	0.0109	CcSEcCtD
Boceprevir—Muscle spasms—Topotecan—cervical cancer	0.00164	0.0108	CcSEcCtD
Boceprevir—CTSL—Primary Focal Segmental Glomerulosclerosis FSGS—CTNNB1—cervical cancer	0.00163	0.016	CbGpPWpGaD
Boceprevir—Ill-defined disorder—Topotecan—cervical cancer	0.00159	0.0104	CcSEcCtD
Boceprevir—Anaemia—Topotecan—cervical cancer	0.00158	0.0104	CcSEcCtD
Boceprevir—Angioedema—Topotecan—cervical cancer	0.00156	0.0103	CcSEcCtD
Boceprevir—Malaise—Topotecan—cervical cancer	0.00154	0.0101	CcSEcCtD
Boceprevir—Leukopenia—Topotecan—cervical cancer	0.00153	0.0101	CcSEcCtD
Boceprevir—CYP3A4—renal system—cervical cancer	0.0015	0.00416	CbGeAlD
Boceprevir—Cough—Topotecan—cervical cancer	0.00149	0.0098	CcSEcCtD
Boceprevir—CYP3A5—female gonad—cervical cancer	0.00146	0.00403	CbGeAlD
Boceprevir—Myalgia—Topotecan—cervical cancer	0.00145	0.00956	CcSEcCtD
Boceprevir—Chest pain—Topotecan—cervical cancer	0.00145	0.00956	CcSEcCtD
Boceprevir—Arthralgia—Topotecan—cervical cancer	0.00145	0.00956	CcSEcCtD
Boceprevir—CYP3A5—vagina—cervical cancer	0.00145	0.00401	CbGeAlD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00144	0.0095	CcSEcCtD
Boceprevir—Discomfort—Topotecan—cervical cancer	0.00144	0.00945	CcSEcCtD
Boceprevir—CTSV—Degradation of the extracellular matrix—CASP3—cervical cancer	0.00143	0.014	CbGpPWpGaD
Boceprevir—CTSL—Degradation of the extracellular matrix—CASP3—cervical cancer	0.00143	0.014	CbGpPWpGaD
Boceprevir—CMA1—Signaling by SCF-KIT—FGFR3—cervical cancer	0.00142	0.014	CbGpPWpGaD
Boceprevir—Infection—Topotecan—cervical cancer	0.00139	0.00911	CcSEcCtD
Boceprevir—Nervous system disorder—Topotecan—cervical cancer	0.00137	0.00899	CcSEcCtD
Boceprevir—Thrombocytopenia—Topotecan—cervical cancer	0.00137	0.00898	CcSEcCtD
Boceprevir—Skin disorder—Topotecan—cervical cancer	0.00135	0.00891	CcSEcCtD
Boceprevir—Hyperhidrosis—Topotecan—cervical cancer	0.00135	0.00886	CcSEcCtD
Boceprevir—CTSL—Adaptive Immune System—UBE3A—cervical cancer	0.00133	0.0131	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—UBE3A—cervical cancer	0.00133	0.0131	CbGpPWpGaD
Boceprevir—CMA1—Peptide hormone metabolism—CTNNB1—cervical cancer	0.00133	0.013	CbGpPWpGaD
Boceprevir—CMA1—Degradation of the extracellular matrix—CASP3—cervical cancer	0.00133	0.013	CbGpPWpGaD
Boceprevir—CTSL—Toll-Like Receptors Cascades—CASP8—cervical cancer	0.0013	0.0128	CbGpPWpGaD
Boceprevir—CTSV—Toll-Like Receptors Cascades—CASP8—cervical cancer	0.0013	0.0128	CbGpPWpGaD
Boceprevir—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00127	0.00835	CcSEcCtD
Boceprevir—Paraesthesia—Topotecan—cervical cancer	0.00125	0.00823	CcSEcCtD
Boceprevir—Dyspnoea—Topotecan—cervical cancer	0.00124	0.00817	CcSEcCtD
Boceprevir—Dyspepsia—Topotecan—cervical cancer	0.00123	0.00807	CcSEcCtD
Boceprevir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.00123	0.0121	CbGpPWpGaD
Boceprevir—Decreased appetite—Topotecan—cervical cancer	0.00121	0.00797	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Topotecan—cervical cancer	0.0012	0.00792	CcSEcCtD
Boceprevir—Fatigue—Topotecan—cervical cancer	0.0012	0.00791	CcSEcCtD
Boceprevir—CYP3A4—female reproductive system—cervical cancer	0.0012	0.00333	CbGeAlD
Boceprevir—Constipation—Topotecan—cervical cancer	0.00119	0.00784	CcSEcCtD
Boceprevir—Pain—Topotecan—cervical cancer	0.00119	0.00784	CcSEcCtD
Boceprevir—CTSK—Degradation of the extracellular matrix—CASP3—cervical cancer	0.00118	0.0116	CbGpPWpGaD
Boceprevir—Feeling abnormal—Topotecan—cervical cancer	0.00115	0.00756	CcSEcCtD
Boceprevir—ABCB1—epithelium—cervical cancer	0.00114	0.00317	CbGeAlD
Boceprevir—Gastrointestinal pain—Topotecan—cervical cancer	0.00114	0.0075	CcSEcCtD
Boceprevir—ABCB1—uterine cervix—cervical cancer	0.00113	0.00314	CbGeAlD
Boceprevir—Urticaria—Topotecan—cervical cancer	0.00111	0.00728	CcSEcCtD
Boceprevir—CTSK—Adaptive Immune System—UBE3A—cervical cancer	0.0011	0.0109	CbGpPWpGaD
Boceprevir—Body temperature increased—Topotecan—cervical cancer	0.0011	0.00725	CcSEcCtD
Boceprevir—Abdominal pain—Topotecan—cervical cancer	0.0011	0.00725	CcSEcCtD
Boceprevir—ABCB1—decidua—cervical cancer	0.00108	0.003	CbGeAlD
Boceprevir—CTSK—Toll-Like Receptors Cascades—CASP8—cervical cancer	0.00108	0.0106	CbGpPWpGaD
Boceprevir—ABCB1—renal system—cervical cancer	0.00106	0.00294	CbGeAlD
Boceprevir—Hypersensitivity—Topotecan—cervical cancer	0.00103	0.00676	CcSEcCtD
Boceprevir—ABCB1—endometrium—cervical cancer	0.00103	0.00284	CbGeAlD
Boceprevir—Asthenia—Topotecan—cervical cancer	0.001	0.00658	CcSEcCtD
Boceprevir—CMA1—Signaling by SCF-KIT—MTOR—cervical cancer	0.000997	0.00982	CbGpPWpGaD
Boceprevir—ABCB1—mammalian vulva—cervical cancer	0.000993	0.00275	CbGeAlD
Boceprevir—Pruritus—Topotecan—cervical cancer	0.000987	0.00649	CcSEcCtD
Boceprevir—CTSS—Degradation of the extracellular matrix—CASP3—cervical cancer	0.000973	0.00957	CbGpPWpGaD
Boceprevir—Diarrhoea—Topotecan—cervical cancer	0.000954	0.00627	CcSEcCtD
Boceprevir—ABCB1—uterus—cervical cancer	0.000946	0.00262	CbGeAlD
Boceprevir—Dizziness—Topotecan—cervical cancer	0.000922	0.00606	CcSEcCtD
Boceprevir—CTSS—Adaptive Immune System—UBE3A—cervical cancer	0.000909	0.00895	CbGpPWpGaD
Boceprevir—CTSS—Toll-Like Receptors Cascades—CASP8—cervical cancer	0.00089	0.00876	CbGpPWpGaD
Boceprevir—Vomiting—Topotecan—cervical cancer	0.000887	0.00583	CcSEcCtD
Boceprevir—Rash—Topotecan—cervical cancer	0.000879	0.00578	CcSEcCtD
Boceprevir—Dermatitis—Topotecan—cervical cancer	0.000879	0.00578	CcSEcCtD
Boceprevir—Headache—Topotecan—cervical cancer	0.000874	0.00574	CcSEcCtD
Boceprevir—ABCB1—female reproductive system—cervical cancer	0.00085	0.00236	CbGeAlD
Boceprevir—ABCB1—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.000847	0.00834	CbGpPWpGaD
Boceprevir—Nausea—Topotecan—cervical cancer	0.000828	0.00545	CcSEcCtD
Boceprevir—CTSV—Immune System—UBE3A—cervical cancer	0.000808	0.00795	CbGpPWpGaD
Boceprevir—CTSL—Immune System—UBE3A—cervical cancer	0.000808	0.00795	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—HLA-DPB1—cervical cancer	0.000795	0.00783	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—HLA-DPB1—cervical cancer	0.000795	0.00783	CbGpPWpGaD
Boceprevir—ABCB1—female gonad—cervical cancer	0.000774	0.00214	CbGeAlD
Boceprevir—CMA1—Signaling by SCF-KIT—STAT3—cervical cancer	0.000771	0.00759	CbGpPWpGaD
Boceprevir—ABCB1—vagina—cervical cancer	0.000769	0.00213	CbGeAlD
Boceprevir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000755	0.00743	CbGpPWpGaD
Boceprevir—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.000727	0.00716	CbGpPWpGaD
Boceprevir—CMA1—Signaling by SCF-KIT—EGFR—cervical cancer	0.0007	0.00689	CbGpPWpGaD
Boceprevir—CTSK—Immune System—UBE3A—cervical cancer	0.000669	0.00659	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—HLA-DPB1—cervical cancer	0.000659	0.00649	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—TAAR6—cervical cancer	0.000631	0.00622	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—HLA-DQB1—cervical cancer	0.000621	0.00611	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—HLA-DQB1—cervical cancer	0.000621	0.00611	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—CASP3—cervical cancer	0.000597	0.00588	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—CASP3—cervical cancer	0.000597	0.00588	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—CD8A—cervical cancer	0.00058	0.00571	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—CD8A—cervical cancer	0.00058	0.00571	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—CASP3—cervical cancer	0.000555	0.00547	CbGpPWpGaD
Boceprevir—CTSS—Immune System—UBE3A—cervical cancer	0.000551	0.00543	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—HLA-DPB1—cervical cancer	0.000543	0.00534	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—HLA-DQB1—cervical cancer	0.000514	0.00506	CbGpPWpGaD
Boceprevir—ABCB1—lymph node—cervical cancer	0.000497	0.00138	CbGeAlD
Boceprevir—CTSK—Extracellular matrix organization—CASP3—cervical cancer	0.000495	0.00487	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—FGFR3—cervical cancer	0.000494	0.00486	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—FGFR3—cervical cancer	0.000494	0.00486	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—WNT2—cervical cancer	0.000493	0.00485	CbGpPWpGaD
Boceprevir—CTSV—Immune System—HLA-DPB1—cervical cancer	0.000482	0.00475	CbGpPWpGaD
Boceprevir—CTSL—Immune System—HLA-DPB1—cervical cancer	0.000482	0.00475	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—CD8A—cervical cancer	0.00048	0.00473	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—FGFR3—cervical cancer	0.000474	0.00467	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—FGFR3—cervical cancer	0.000474	0.00467	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—HLA-DPB1—cervical cancer	0.000457	0.0045	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—AKAP13—cervical cancer	0.000433	0.00426	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—HLA-DQB1—cervical cancer	0.000424	0.00417	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—CASP8—cervical cancer	0.000422	0.00416	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—CASP8—cervical cancer	0.000422	0.00416	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—FGFR3—cervical cancer	0.000409	0.00403	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—CASP3—cervical cancer	0.000408	0.00401	CbGpPWpGaD
Boceprevir—CTSK—Immune System—HLA-DPB1—cervical cancer	0.0004	0.00393	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—CD8A—cervical cancer	0.000396	0.00389	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—FGFR3—cervical cancer	0.000393	0.00387	CbGpPWpGaD
Boceprevir—CTSV—Immune System—HLA-DQB1—cervical cancer	0.000377	0.00371	CbGpPWpGaD
Boceprevir—CTSL—Immune System—HLA-DQB1—cervical cancer	0.000377	0.00371	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—WNT5A—cervical cancer	0.000374	0.00368	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—HLA-DQB1—cervical cancer	0.000357	0.00351	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CD8A—cervical cancer	0.000352	0.00346	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CD8A—cervical cancer	0.000352	0.00346	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—CASP8—cervical cancer	0.00035	0.00344	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—MTOR—cervical cancer	0.000347	0.00342	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—MTOR—cervical cancer	0.000347	0.00342	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—CD4—cervical cancer	0.000347	0.00341	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—CD4—cervical cancer	0.000347	0.00341	CbGpPWpGaD
Boceprevir—ABCB1—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.000343	0.00338	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—FGFR3—cervical cancer	0.000337	0.00332	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—MTOR—cervical cancer	0.000334	0.00328	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—MTOR—cervical cancer	0.000334	0.00328	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—CD4—cervical cancer	0.000333	0.00328	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—CD4—cervical cancer	0.000333	0.00328	CbGpPWpGaD
Boceprevir—CTSS—Immune System—HLA-DPB1—cervical cancer	0.000329	0.00324	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—FGFR3—cervical cancer	0.000324	0.00319	CbGpPWpGaD
Boceprevir—CTSK—Immune System—HLA-DQB1—cervical cancer	0.000312	0.00307	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—CTNNB1—cervical cancer	0.000308	0.00303	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—CTNNB1—cervical cancer	0.000308	0.00303	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000308	0.00303	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CD8A—cervical cancer	0.000291	0.00287	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—CASP8—cervical cancer	0.000288	0.00284	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—MTOR—cervical cancer	0.000288	0.00283	CbGpPWpGaD
Boceprevir—CTSL—Immune System—FGFR3—cervical cancer	0.000288	0.00283	CbGpPWpGaD
Boceprevir—CTSV—Immune System—FGFR3—cervical cancer	0.000288	0.00283	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—CD4—cervical cancer	0.000287	0.00283	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—MTOR—cervical cancer	0.000276	0.00272	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—CD4—cervical cancer	0.000276	0.00272	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—NOTCH2—cervical cancer	0.000262	0.00258	CbGpPWpGaD
Boceprevir—CTSS—Immune System—HLA-DQB1—cervical cancer	0.000257	0.00253	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—CTNNB1—cervical cancer	0.000255	0.00251	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—CTNNB1—cervical cancer	0.00025	0.00246	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CASP8—cervical cancer	0.000246	0.00242	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CASP8—cervical cancer	0.000246	0.00242	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—EGFR—cervical cancer	0.000244	0.0024	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—EGFR—cervical cancer	0.000244	0.0024	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CD8A—cervical cancer	0.00024	0.00236	CbGpPWpGaD
Boceprevir—CTSK—Immune System—FGFR3—cervical cancer	0.000238	0.00235	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—MTOR—cervical cancer	0.000237	0.00233	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—CD4—cervical cancer	0.000237	0.00233	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—EGFR—cervical cancer	0.000234	0.00231	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—EGFR—cervical cancer	0.000234	0.00231	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—CASP8—cervical cancer	0.000233	0.00229	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—MTOR—cervical cancer	0.000228	0.00224	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—CD4—cervical cancer	0.000227	0.00224	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—HES1—cervical cancer	0.000215	0.00212	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—CTNNB1—cervical cancer	0.00021	0.00207	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CASP8—cervical cancer	0.000204	0.00201	CbGpPWpGaD
Boceprevir—CTSL—Immune System—MTOR—cervical cancer	0.000202	0.00199	CbGpPWpGaD
Boceprevir—CTSV—Immune System—MTOR—cervical cancer	0.000202	0.00199	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—EGFR—cervical cancer	0.000202	0.00199	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CD4—cervical cancer	0.000202	0.00199	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CD4—cervical cancer	0.000202	0.00199	CbGpPWpGaD
Boceprevir—CTSS—Immune System—FGFR3—cervical cancer	0.000196	0.00193	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—EGFR—cervical cancer	0.000194	0.00191	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—TERT—cervical cancer	0.000188	0.00185	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CTNNB1—cervical cancer	0.000179	0.00177	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CTNNB1—cervical cancer	0.000179	0.00177	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—CASP3—cervical cancer	0.000176	0.00174	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—FGFR3—cervical cancer	0.000173	0.0017	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CASP8—cervical cancer	0.000168	0.00165	CbGpPWpGaD
Boceprevir—CTSK—Immune System—MTOR—cervical cancer	0.000168	0.00165	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CD4—cervical cancer	0.000167	0.00165	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—EGFR—cervical cancer	0.000167	0.00164	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—NOTCH1—cervical cancer	0.000162	0.0016	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—EGFR—cervical cancer	0.00016	0.00157	CbGpPWpGaD
Boceprevir—CTSL—Immune System—STAT3—cervical cancer	0.000156	0.00154	CbGpPWpGaD
Boceprevir—CTSV—Immune System—STAT3—cervical cancer	0.000156	0.00154	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CTNNB1—cervical cancer	0.000149	0.00146	CbGpPWpGaD
Boceprevir—CTSV—Immune System—EGFR—cervical cancer	0.000142	0.0014	CbGpPWpGaD
Boceprevir—CTSL—Immune System—EGFR—cervical cancer	0.000142	0.0014	CbGpPWpGaD
Boceprevir—CTSS—Immune System—MTOR—cervical cancer	0.000138	0.00136	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CD4—cervical cancer	0.000138	0.00136	CbGpPWpGaD
Boceprevir—CTSK—Immune System—STAT3—cervical cancer	0.00013	0.00128	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CTNNB1—cervical cancer	0.000122	0.00121	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—MTOR—cervical cancer	0.000122	0.0012	CbGpPWpGaD
Boceprevir—CTSK—Immune System—EGFR—cervical cancer	0.000118	0.00116	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000115	0.00113	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CASP3—cervical cancer	0.000112	0.0011	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CTNNB1—cervical cancer	0.000108	0.00106	CbGpPWpGaD
Boceprevir—CTSS—Immune System—STAT3—cervical cancer	0.000107	0.00105	CbGpPWpGaD
Boceprevir—CTSS—Immune System—EGFR—cervical cancer	9.7e-05	0.000955	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—STAT3—cervical cancer	9.4e-05	0.000925	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CA9—cervical cancer	8.93e-05	0.000879	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	8.7e-05	0.000857	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—EGFR—cervical cancer	8.54e-05	0.000841	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	8.39e-05	0.000826	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—TP53—cervical cancer	7.17e-05	0.000706	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CA9—cervical cancer	6.74e-05	0.000663	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	6.65e-05	0.000654	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	5.58e-05	0.000549	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CA9—cervical cancer	4.15e-05	0.000409	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—MTHFR—cervical cancer	3.62e-05	0.000357	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—MTHFR—cervical cancer	2.73e-05	0.000269	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—MTHFR—cervical cancer	1.68e-05	0.000166	CbGpPWpGaD
